3 Reviews
Pretty good company to work at. Nice office and benefits
It is still a small company so don't expect to get a full benefits package
Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
Coherent Market Insights has announced new analysis on Antibodies Market Status 2022-2028 which has been prepared based on an in-depth market analysis